SME Times is powered by   
Search News
Just in:   • PM Modi hails EU delegation's visit as 'unprecedented,' boosting trade, tech, and connectivity.  • The Indian stock market plunged amid weak global cues  • EU Chief in India to Push Free Trade Deal Amid Trump Tariff Threat  • India has potential to play key role in new world order, says FM Sitharaman  • US trade tariffs: Domestic challenges remain for China amid high uncertainty 
Last updated: 06 Jan, 2020  

Biocon.9.Thmb.jpg True North to acquire 2.4% stake in Biocon arm

Biocon.9.jpg
   Top Stories
» PM Modi hails EU delegation's visit as 'unprecedented,' boosting trade, tech, and connectivity.
» The Indian stock market plunged amid weak global cues
» EU Chief in India to Push Free Trade Deal Amid Trump Tariff Threat
» India has potential to play key role in new world order, says FM Sitharaman
» Rural India spending more time on learning activities, women take lead: Centre
SME Times News Bureau | 06 Jan, 2020
Pharmaceuticals major Biocon Ltd on Monday said that its subsidiary Biocon Biologics India has approved the acquisition of 2.44 per cent stake in it by private equity firm True North with an investment of Rs 536.25 crore.

In a regulatory filing, Biocon said that the transaction is subject to standard condition precedents including regulatory approvals and post the completion of this transaction, Biocon will hold 96.07 per cent stake in Biocon Biologics. The deal values the unlisted subsidiary at around $3 billion.

"As per the terms of the proposed agreement, True North will invest Rs 536.25 Crore that will eventually translate to a 2.44 per cent minority stake in the biosimilars business post all restructuring, including the filed merger of Biocon Research Ltd with Biocon Biologics, valuing Biocon Biologics at Rs 21,450 crore or $3 billion on a pre-money equity basis," it said.

Commenting on the development, Kiran Mazumdar Shaw, Chairperson and Managing Director of Biocon said: "This investment is an endorsement of the value that Biocon Biologics has demonstrated as a global biosimilars player, having commercializsd three of its molecules in developed markets like EU, the US, Japan and Australia. This is at an important inflection point as we gain commercial success with our first wave of Biosimilar products and invest in the long term through broadening our pipeline, expanding our manufacturing capacity and increasing our commercial footprint."

Biocon Biologics is a fully-integrated ‘pure play' biosimilars organisation and is engaged in developing high-quality, affordable biosimilars aimed at expanding patient access to cutting-edge class of therapies across the world.

True North is an investment company focussed on investing in and transforming mid-sized profitable businesses.
 
Print the Page
Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
84.35
82.60
UK Pound
106.35
102.90
Euro
92.50
89.35
Japanese Yen 55.05 53.40
As on 12 Oct, 2024
  Daily Poll
Do you think Indian businesses will be negatively affected by Trump's America First Policy?
 Yes
 No
 Can't Say
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter